GleamWall
中文EN

SGMT Sagimet Biosciences Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1400118 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY7.5%
TTM EPS YoY33.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-29.5%
ROA-26.0%
ROIC (approx.)-43.4%
Asset turnover—

Leverage & solvency

Liabilities / assets14.1%
Debt / equity0.00x
Current ratio6.34x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-4.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$39.05M$38.44M
SG&A expense$17.84M$16.01M
Operating income-$56.89M-$54.45M
Income tax$0$0
Net income-$51.04M-$45.57M
EPS (basic)-1.58-1.45
EPS (diluted)-1.58-1.45
Weighted avg. shares (diluted)32.35M31.35M
Balance sheet
Cash & equivalents$35.02M$75.84M
Short-term investments$78.10M$75.41M
Current assets$116.40M$152.77M
Total assets$116.48M$160.26M
Current liabilities$5.10M$4.45M
Total liabilities$5.10M$4.45M
Shareholders' equity$111.38M$155.81M
Cash flow statement
Operating cash flow-$45.65M-$42.44M
Investing cash flow$4.56M-$61.68M
Financing cash flow$275,000$104.82M
Stock-based compensation$6.45M$5.29M

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.